ÓSKARE-CAPITAL
11.6.2020 15:02:12 CEST | Business Wire | Press release
ÓSKARE CAPITAL SAS today launches ÓSKARE Fund I together with cannabinoid industry veteran Bruce Linton. The EU based fund targets next generation cannabinoid therapies and related industry infrastructure, leveraging the expertise and track record of the founding team in medicine, engineering, chemistry, venture capital, and intellectual property.
“Based on my partnership with the ÓSKARE CAPITAL team over the last 9 months, I am convinced that Europe has the optimal regulatory and research environment to build the future key players in the global medical cannabinoid industry,” said Bruce Linton, Co-founder and non- Executive Chairman, ÓSKARE CAPITAL, and former CEO and Founder, Canopy Growth. "The ÓSKARE CAPITAL team’s strong scientific background and proven track record in pharma, venture capital and IP protection leverages proprietary deal flow and knowledge of the ecosystem to be successful".
The fund will invest in a diversified portfolio of companies with disruptive technology and strong barriers to entry. The team is supported by a highly experienced senior advisory board (https://oskarecapital.com/team/ ) that provides critical expertise and expands its network. ÓSKARE Fund I is ESG compatible.
Medical grade cannabinoid-based products are already approved and used in Europe to treat conditions such as epilepsy, multiple sclerosis and chronic pain. Now the science and the medical community are driving opportunities in human as well as animal health and wellness.
The team at ÓSKARE CAPITAL has access to leading research teams and companies that have identified new cannabinoid molecules and formulations with therapeutic potential for medical conditions such as anxiety and depression, cancer, autism, ADHD, cardiovascular and inflammatory skin conditions, among others. The fund will invest in the entire value chain as well as look to valorise hemp and cannabis biomass for new sustainable material applications.
The team has already performed a first investment in Denmark’s Octarine Bio .
Innovation and R&D are at the core of EU and UK value generation and core to the Fund opportunity. Cannabinoids will disrupt global markets from food to pharma and ÓSKARE CAPITAL will be the early investor on this wave.
About ÓSKARE CAPITAL SAS – oskarecapital.com
ÓSKARE CAPITAL SAS is a French company which has the French status of CIF (Financial Investment Advisor), ORIAS number 20001206 and regulated by the AMF.
About ÓSKARE FUND I
ÓSKARE Fund I, advised by ÓSKARE CAPITAL SAS, is set up so that investors can readily access innovative opportunities in this space with the protection and transparency an AIFM compatible fund provides. Regulated by the Central Bank of Ireland, Crossroads Capital Management Limited will act as an alternative investment fund manager.
About Crossroads Capital Management Limited – www.crossroadscapital.ie
Crossroads Capital Management Limited, majority owned by Hauck & Aufhäuser Fund Services S.A., is authorised and regulated by the Central Bank of Ireland as a UCITS management company and alternative investment fund manager (AIFM).
This press release is not a marketing communication in the European Union member states or non-member states. This press release is not an offer of securities, products, instruments or services for sale in the United States. We do not make representation that information presented is appropriate for use in all jurisdictions.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200611005098/en/
Social Media:
https://www.facebook.com/%C3%93skare-Capital-102537244481166/?view_public_for=102537244481166
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Angelalign Technology Inc. (6699.HK) Applauds European Court Rejection of Patent Infringement Claim12.5.2026 19:39:00 CEST | Press release
Angelalign Technology Inc. (6699.HK) (“Angel”) (http://www.angelaligner.com) today said it was grateful that the Local Division Düsseldorf (Germany) of the Unified Patent Court rejected a request by Align Technology Inc. (ALGN) for Angel to cease and desist from using its A7 Premolar Extraction Solution. Angel denied that the A7 tooth movement protocol infringes any patents as alleged by Align Technology Inc. (ALGN). The court rejected Align’s request for Angel to preliminarily cease its use of the feature, a decision Angel applauded. “We respect the Düsseldorf Local Division’s ruling and will continue to make our case that Angel has not violated any valid patents,” said Dr. Arno Riße, Angel’s attorney at the Arnold Ruess law firm of Düsseldorf. “We are grateful that the court decided not to grant Align's request for preliminary measures. Angel takes intellectual property rights seriously and is careful not to infringe on legitimate patents.” “We categorically deny the allegations of i
Bharat Forge Signs Long-Term Contract with Embraer for Landing Gear Forgings12.5.2026 18:38:00 CEST | Press release
Bharat Forge Ltd. (BFL) (BSE: 500493, NSE: BHARATFORG), a global leader in advanced forging and precision engineering, today announced a long-term contract with Embraer for the manufacturing and supply of critical landing gear forgings. With this milestone, Bharat Forge becomes the first Indian supplier to join Embraer’s global aerospace supply chain for forged components. Under the agreement, Bharat Forge will supply high-integrity forged components for landing gear systems across Embraer’s commercial and Defence aircraft programs. This engagement establishes a strategic partnership anchored in advanced manufacturing capabilities, precision engineering, and proven expertise in delivering complex, safety-critical components for global aerospace platforms. The long-term contract reflects a shared commitment to quality, reliability, and sustained collaboration, and reinforces Embraer’s confidence in Bharat Forge’s ability to meet stringent global certification standards while consistentl
De' Longhi Group - 6.6% Growth at Constant Exchange Rates and Accelerated Net Profit: Solid Results Fully Support Guidance12.5.2026 18:37:00 CEST | Press release
The Group closed another quarter with robust organic growth, driven by the excellent expansion of the professional division, with turnover growing significantly and representing 18% of the Group's total for the period, and by the positive performance of the household The Board of Directors of De' Longhi S.p.A. approved the consolidated results 1for the first quarter of 2026: In the first quarter the Group achieved: revenues of € 777.7 million, up 3% (+6.6% at constant exchange rates); adjusted 2Ebitda of € 125.9 million, equal to 16.2% of revenues (15.4% in Q1-25); net profit (pertaining to the Group) of € 61.7 million, equal to 7.9% of revenues and up 7.5% compared to the previous year; net financial position at the end of March 2026 of € 720.5 million. CEO Fabio de' Longhi commented: “The start of 2026 was marked by solid revenue growth of 6.6% at constant exchange rates, continuing the excellent performance achieved in recent years. The professional division's strong expansion susta
Multi-Color Corporation Successfully Completes Comprehensive Financial Restructuring12.5.2026 18:09:00 CEST | Press release
Company Emerges Stronger, Well-Positioned to Execute Long-Term Strategy With Significantly Deleveraged Balance Sheet Multi-Color Corporation ("MCC" or the "Company") today announced the successful completion of the Company’s financial restructuring process and emergence from its prepackaged Chapter 11 process. The Company’s prepackaged restructuring reduced net debt by approximately $3.8 billion, reduced annualized cash interest expense by more than $330 million, and extended long-term debt maturities to 2033. More than 99% of voting stakeholders voted to accept MCC’s Plan of Reorganization. Upon emergence, MCC also received a significant $889 million new common and preferred equity investment from CD&R and a group of MCC’s existing secured lenders to support MCC’s long-term growth and investment. "Today marks a significant milestone for MCC, as well as our customers, teammates, and partners who have supported us throughout this process,” said Hassan Rmaile, President and Chief Executi
New Cessna Caravans to Boost USDA’s Fight Against Crop-Damaging Insects12.5.2026 17:00:00 CEST | Press release
Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, today announced that the U.S. Department of Agriculture (USDA) Animal and Plant Health Inspection Service (APHIS) has ordered three Cessna Caravan aircraft to support its sterile insect release program protecting citrus crops along the Rio Grande River in southern Texas. The new aircraft are expected to be delivered in 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260512676348/en/ Mission-Ready: The Cessna Caravan joins USDA’s fight to protect Texas citrus from invasive pests APHIS will use the Caravans to carry and release sterile insects that help prevent the spread of destructive pests, including fruit flies. The environmentally friendly technique helps safeguard fruit-bearing trees, reduce crop damage and protect agricultural industries that rely on healthy harvests. “These aircraft will help APHIS reach remote areas and carry out their important mission o
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom